Tuesday, February 07, 2012

Study: Pfizer’s Breast-Cancer Drug Worsens Bone Loss in Older Women

From Bloomberg:

According to a recent study, Aromasin worsened bone loss in post-menopausal women, raising the chance of fractures and calling into question whether the pill’s prevention benefits outweigh its risks.
In a trial among 351 women at risk of developing breast cancer, those who received Aromasin lost about three times more bone-mineral density after two years than those who took a placebo, researchers wrote  in The Lancet Oncology.